ライブ
FierceBiotechAstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposalEndpoints NewsHouse panel calls to ban China trial data from FDA drug trial applicationsEndpoints NewsCourt dismisses part of Lilly lawsuit against Empower, some claims can proceedEndpoints NewsSupreme Court questions how far generics makers can go with 'skinny label' drugsMerck KGaAMerck KGaA taps into Remepy’s Hybrid Drug platform - The Pharma LetterGE HealthCareGE HealthCare’s stock plunges 13% as supply chain costs bite - Medical Device NetworkBioPharma DiveMerck still sees ‘compelling’ outlook for Terns leukemia drugMerck & Co.Merck & Co lifts outlook as Keytruda growth offsets acquisition hit - The Pharma LetterCellProteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte functionCellDifferential inhibition of <em>Morbillivirus</em> and <em>Henipavirus</em> polymerases by ERDRP-0519 and structure-guided inhibitor optimizationBioWorldAppointments and advancements for April 30, 2026BioWorldFinancings for April 30, 2026
eLife 2026年4月30日

Bivalent mRNA booster encoding virus-like particles elicits potent polyclass receptor-binding domain antibodies in pre-vaccinated mice

Bivalent mRNA booster encoding virus-like particles elicits potent polyclass receptor-binding domain antibodies in pre-vaccinated mice

原文
本文は利用できません。元の情報源をご確認ください。